{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:06:56Z","timestamp":1792206416554,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":1735,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010738","name":"Ablynx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1111\/jth.13716","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T12:37:39Z","timestamp":1493210259000},"page":"1448-1452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"F.","family":"Peyvandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Scully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Kremer Hovinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kn\u00f6bl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cataland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"De Beuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Callewaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"De Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.","family":"Zeldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13716_bb0010","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"George","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.13716_bb0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","article-title":"von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura","volume":"112","author":"Sadler","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.13716_bb0020","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/trf.13586","article-title":"Prognostic risk\u2010stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012","volume":"56","author":"Goel","year":"2016","journal-title":"Transfusion"},{"key":"10.1111\/jth.13716_bb0025","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2014-10-605493","article-title":"Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in\u2010hospital mortality","volume":"125","author":"Goel","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.13716_bb0030","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.13716_bb0035","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","article-title":"Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency\u2010associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"Benhamou","year":"2012","journal-title":"Haematologica"},{"key":"10.1111\/jth.13716_bb0040","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13716_bb0045","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMe1515876","article-title":"von Willebrand factor \u2013 a new target for TTP treatment?","volume":"374","author":"Veyradier","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13716_bb0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13716_bb0055","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13716_bb0060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/trf.12263","article-title":"High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll\u2010like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center","volume":"54","author":"Morgand","year":"2014","journal-title":"Transfusion"},{"key":"10.1111\/jth.13716_bb0065","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jth.12790","article-title":"Cardiac troponin\u2010I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"13","author":"Benhamou","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13716_bb0070","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00277-010-0968-3","article-title":"Long\u2010term follow\u2010up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab","volume":"89","author":"Chemnitz","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1111\/jth.13716_bb0075","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","article-title":"How I treat refractory thrombotic thrombocytopenic purpura","volume":"125","author":"Sayani","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.13716_bb0080","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccell.2011.08.009","article-title":"Comprehensive care of adults with acute ischemic stroke","volume":"23","author":"Hughes","year":"2011","journal-title":"Crit Care Nurs Clin North Am"},{"key":"10.1111\/jth.13716_bb0085","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1161\/CIRCULATIONAHA.113.004046","article-title":"The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study","volume":"129","author":"Moran","year":"2014","journal-title":"Circulation"},{"key":"10.1111\/jth.13716_bb0090","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ajh.24060","article-title":"Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura","volume":"90","author":"Han","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.13716_bb0095","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long\u2010term follow\u2010up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.13716_bb0100","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1537-2995.2009.02101.x","article-title":"Cognitive deficits after recovery from thrombotic thrombocytopenic purpura","volume":"49","author":"Kennedy","year":"2009","journal-title":"Transfusion"},{"key":"10.1111\/jth.13716_bb0105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1537-2995.2008.01938.x","article-title":"Long\u2010term deficits in health\u2010related quality of life after recovery from thrombotic thrombocytopenic purpura","volume":"49","author":"Lewis","year":"2009","journal-title":"Transfusion"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13716","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.13716","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.13716","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622043069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622043069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.13716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:18:21Z","timestamp":1761535101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622043069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1538783622043069"],"URL":"https:\/\/doi.org\/10.1111\/jth.13716","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 The Authors. Journal of Thrombosis and Haemostasis. Published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}